---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-25-000046"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:51:02.521931+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "low"
source: SEC EDGAR
---

# Elicio Therapeutics reports year-end 2024 results; press release text unreadable

## Summary
- Filing announces financial results for year ended Dec 31, 2024 and corporate updates.
- Attached press release (Exhibit 99.1) contains extensive encoding corruption; specific figures not extractable.
- No legible quantitative guidance or material non-financial updates identified in the exhibit.
- Management change or other items not mentioned; only operational update alluded to.

## SEC filing metadata
- accession: 0001601485-25-000046
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: low
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000046/0001601485-25-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000046/angn-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-25-000046
- JSON: https://secwatch.observer/filing/0001601485-25-000046.json
- Plain text: https://secwatch.observer/filing/0001601485-25-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.